Destiny Pharma, Glen Goodman and Alan Green
Do you want to get instant company alerts to the front screen of your smartphone? Download the Vox Markets app here: www.VoxMarkets.co.uk/app
On today's Vox Markets Podcast:Destiny Pharma, Glen Goodman and Alan Green
Neil Clark, Chief Executive Officer of Destiny Pharma #DEST provides updates on the Phase 2b clinical study of their lead asset and other parts of the business.
Destiny Pharma is an established, clinical stage, innovative biotechnology company focused on the development and commercialisation of novel medicines that can prevent life threatening infections.
The company's lead programme is undergoing a Phase 2b clinical trial and is targeting the prevention of post-surgical hospital infections including MRSA. The XF drug candidates are being developed for the prevention and treatment of life-threatening infections caused by antibiotic‑resistant bacteria, often referred to as "superbugs". Tackling anti-microbial resistance has become a global imperative recognised by the World Health Organization (WHO) and the United Nations, as well as the G7 and the G20 countries. Destiny Pharma is also collaborating with SporeGen® to co-develop a novel, preventative product for COVID-19.
Glen Goodman, former ITV News Business correspondent and now author of, "The Crypto Trader", covers this week’s Bitcoin, Blockchain and Cryptocurrency news.
(Interview starts at 12 minutes 37 seconds)
Alan Green CEO of Brand Communications talks about:
(Interview starts at 37 minutes 46 seconds)
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.